Latest Kura Oncology News & Updates
See the latest news and media coverage for Kura Oncology. We track all announcements, press releases, and industry mentions in real time, all in one place.
Precision oncology therapeutics developer
kuraoncology.com- Headquarters
- San Diego, United States
- Founded year
- 2014
- Company type
- Public company
- Number of employees
- 300–500
Last updated
Latest news about Kura Oncology
In short: Kura Oncology achieved FDA approval for KOMZIFTI (ziftomenib) and secured significant milestone payments while advancing its clinical pipeline.
Company announcements
-
Kura Oncology initiates Japanese Phase 2 trial of ziftomenib
Kyowa Kirin doses first patient in registrational trial for R/R NPM1-m AML. Plans regulatory filing post-trial. Ziftomenib FDA-approved in US as KOMZIFTI.
-
Kura Oncology reports darlifarnib plus cabozantinib activity in ccRCC patients
Subset analysis shows 44% ORR, 94% DCR in cabozantinib-pretreated patients. Tumor shrinkage in 75%. Manageable safety profile. Data from FIT-001 trial presented at IKCS Europe.
-
Kura Oncology presents darlifarnib plus cabozantinib data
Data from FIT-001 trial in ccRCC patients will be presented at IKCS Europe 2026 on April 17. Builds on ESMO 2025 findings.
-
Kura Oncology reports Q4 and full year 2025 financial results
KOMZIFTI generates $2.1M revenue; cash at $667.2M; multiple 2026 clinical milestones planned. Net loss $81M.
Media coverage
-
Kura Oncology to Report First Quarter 2026 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will...
-
Kura Oncology to Report First Quarter 2026 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will...
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced...
-
KURA Kura Oncology reports wider than expected Q4 2025 loss as shares rise modes...
Our platform provides morning reports, sector updates, earnings previews, and market outlook analysis. Stay ahead of the market with daily insights from our expert team...
Track Kura Oncology and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Kura Oncology competitors & trending companies
Browse news for competitors to Kura Oncology and other trending companies.
Eikon
Alligator Bioscience
Sprint Bioscience
Candel Therapeutics
Imugene
Oncopeptides
Aura Biosciences
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo